FibroGen Inc (NASDAQ:FGEN)
| 44.35 Delayed Data As of Jan 17 |  -0.24 / -0.54%Today’s Change | 32.33 Today|||52-Week Range 61.23 | +3.40% Year-to-Date |
Latest FGEN News | Press Releases
| FibroGen Appoints Enrique Conterno as Its New CEO Jan 06 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 44.59 |
| Today’s open | 44.96 |
| Day’s range | 44.30 - 45.21 |
| Volume | 835,095 |
| Average volume (3 months) | 743,371 |
| Market cap | $3.9B |
Data as of 4:00pm ET, 01/17/2020
Growth & Valuation
| Earnings growth (last year) | +40.55% |
| Earnings growth (this year) | +77.64% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +69.46% |
| P/E ratio | 92.4 |
| Price/Sales | 18.27 |
| Price/Book | 7.44 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ADPTAdaptive Biotechnolo... | +0.84 | +3.07% |
| MEDPMedpace Holdings Inc | -0.09 | -0.10% |
| EXELExelixis Inc | -0.62 | -3.03% |
| SYNHSyneos Health Inc | +0.13 | +0.20% |
Data as of 4:00pm ET, 01/17/2020
Financials
| Next reporting date | February 26, 2020 |
| EPS forecast (this quarter) | -$0.45 |
| Annual revenue (last year) | $213.0M |
| Annual profit (last year) | -$86.4M |
| Net profit margin | -40.58% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Francisco, California |
Forecasts
